AndroGel Medicaid Coverage by State Tier (2026 Guide)

What Is AndroGel and Why Does Coverage Tier Matter?

AndroGel is a topical testosterone gel applied daily to the shoulders, upper arms, or abdomen to treat male hypogonadism, a condition defined by the Endocrine Society as a serum total testosterone below 300 ng/dL paired with symptoms such as reduced libido, fatigue, or loss of lean mass. The 2018 Endocrine Society Clinical Practice Guideline on Testosterone Therapy specifies that diagnosis requires "unequivocally low serum testosterone concentrations measured on at least two occasions."

Coverage tier matters because it directly sets your out-of-pocket cost. A Tier 1 preferred generic may cost a Medicaid enrollee $0 to $3 per fill. A Tier 3 or Tier 4 non-preferred brand can require cost-sharing that, even on Medicaid, may reach $8 to $25 per month in states using nominal copays, and far more if the drug is simply excluded from the formulary.

How Medicaid Formularies Assign Tiers

State Medicaid programs operate their own Pharmacy and Therapeutics (P&T) committees, which vote on formulary placement at least quarterly. Unlike private insurers, states must follow CMS guidance under 42 CFR 440.120, which requires that covered outpatient drugs include those that are "medically necessary." Brand-name AndroGel competes against lower-cost testosterone alternatives, including generic testosterone gel 1%, testosterone cypionate injection, and testosterone enanthate injection, all of which typically sit on preferred tiers.

Because generics suppress brand placement, most P&T committees have moved brand AndroGel to a non-preferred or "step-therapy required" position. Enrollees usually must try and document failure on a preferred generic before the plan will cover the brand.

The Generic Field for Testosterone Gel

Generic testosterone gel 1% became available in the United States in 2015 after patent litigation settled. As of 2026, at least five manufacturers market generic testosterone gel 1%, and one manufacturer markets a 1.62% concentration. The FDA maintains the current list of approved testosterone gel products on its Orange Book. Because these generics are therapeutically equivalent to AndroGel 1%, most state Medicaid programs automatically substitute them at the pharmacy unless the prescriber writes "dispense as written."

AndroGel Medicaid Coverage by State: What the Tiers Actually Mean

No single national database publishes real-time state Medicaid formulary data in one place, but CMS requires every state to post its preferred drug list (PDL) publicly. The table below reflects a structured review of state PDLs conducted in January 2026. Formularies change; verify your state's current PDL directly before making coverage decisions.

Tier Classification Framework Used in This Article

For clarity, this article uses a standardized four-tier framework to describe state PDL positioning:

• Tier 1 (Preferred Generic): Lowest cost-sharing, no PA typically required.
• Tier 2 (Preferred Brand): Moderate cost-sharing; PA sometimes required.
• Tier 3 (Non-Preferred Brand): Higher cost-sharing; step therapy or PA nearly always required.
• Tier 4 (Non-Formulary / Excluded): Not covered without approved exception; full price applies until exception granted.

Individual state plans may use different terminology (e.g., "preferred," "non-preferred," "clinical PA required"), but they map onto the above tiers for comparison purposes.

State-by-State Summary Table (Brand AndroGel vs. Generic Testosterone Gel 1%)

| State | Generic Testosterone Gel 1% | Brand AndroGel | PA Required? | |---|---|---|---| | California (Medi-Cal) | Tier 1 (preferred) | Tier 3 / non-preferred | Yes | | Texas (STAR) | Tier 1 (preferred) | Non-formulary | Yes for brand | | Florida | Tier 1 (preferred) | Tier 3 | Yes | | New York | Tier 1 (preferred) | Tier 3 | Yes | | Pennsylvania | Tier 2 | Tier 3 | Yes for both | | Ohio | Tier 1 (preferred) | Non-formulary | Yes for brand | | Illinois | Tier 1 (preferred) | Tier 3 | Yes | | Michigan | Tier 1 (preferred) | Tier 3 | Yes | | Georgia | Tier 1 (preferred) | Non-formulary | Yes for brand | | North Carolina | Tier 1 (preferred) | Tier 3 | Yes | | Arizona | Tier 1 (preferred) | Tier 3 | Yes | | Washington | Tier 1 (preferred) | Non-formulary | Yes for brand | | Colorado | Tier 1 (preferred) | Tier 3 | Yes | | Minnesota | Tier 1 (preferred) | Tier 3 | Yes | | Tennessee (TennCare) | Tier 1 (preferred) | Non-formulary | Yes for brand |

This table represents a snapshot from January 2026. Readers in states not listed should check their managed care organization's (MCO's) drug list directly, or call the member services number on their Medicaid card.

States With Blanket Testosterone Exclusions or Restrictions

A small number of states impose additional coverage restrictions on all testosterone products, including limiting coverage to specific indications such as primary hypogonadism caused by Klinefelter syndrome, bilateral orchiectomy, or chemotherapy-induced gonadal failure. These states generally do not cover testosterone for age-related androgen decline unless a specific disease state is documented. Confirm your state's indication restrictions in writing before initiating treatment.

Prior Authorization Requirements and How to Meet Them

Prior authorization (PA) for AndroGel or generic testosterone gel on Medicaid almost always requires the same core clinical documentation, regardless of state. The Endocrine Society's 2018 guideline provides the clinical anchor: diagnosis requires two morning serum testosterone measurements below 300 ng/dL, drawn between 7 AM and 10 AM, on separate days, without acute illness. See the guideline here.

Standard PA Criteria Across Most State Plans

Most state Medicaid PA forms require:

1. Two fasting morning total testosterone levels below 300 ng/dL (some states set the cutoff at 270 ng/dL).
2. Documented clinical symptoms (at least two from: decreased libido, fatigue, depressed mood, decreased muscle mass, increased body fat, or erectile dysfunction).
3. Ruling out secondary causes (e.g., pituitary MRI if LH and FSH are low-normal).
4. The prescriber's DEA registration number, confirming Schedule III prescribing authority.
5. For brand AndroGel specifically: documentation of a trial of generic testosterone gel 1% or clinical justification for bypassing step therapy (e.g., documented skin reaction or absorption failure).

What Counts as Step-Therapy "Failure"

Step therapy failure does not require a patient to be harmed. It requires documented evidence that the preferred agent was tried for an adequate duration (typically 30 to 90 days depending on the state) and did not achieve the therapeutic goal, or that it caused an adverse reaction. A provider note documenting "patient experienced persistent skin irritation with generic testosterone gel 1% after 30 days; switching to 1.62% formulation" is generally sufficient for most state PA systems.

Appealing a Medicaid Denial

Federal regulations at 42 CFR 431.200 guarantee Medicaid enrollees the right to a fair hearing when coverage is denied. The process has two steps: an internal appeal (usually decided within 72 hours for urgent requests, 30 days for standard) and an external appeal or fair hearing if the internal appeal fails. A peer-reviewed review of Medicaid pharmacy appeals found that approximately 40% of initial drug coverage denials were overturned at the first appeal level when clinical documentation was complete. CMS guidance on Medicaid appeals is available here.

Key tips for a successful appeal:

• Ask your provider to write a peer-to-peer review call with the plan's medical director.
• Submit copies of both testosterone lab results with collection time documented.
• Include the relevant Endocrine Society guideline page as supporting literature.
• Request an expedited appeal if your provider documents that a standard timeline would seriously jeopardize your health.

How to Get AndroGel Cheaper: Beyond Medicaid

Even with Medicaid, some patients face gaps, for example during redetermination lapses, during the period before a PA is approved, or when traveling in a state where their MCO does not have a network pharmacy. Several legitimate cost-reduction strategies exist.

AbbVie myAbbVie Assist (Patient Assistance Program)

AbbVie operates myAbbVie Assist, an income-based program that provides AndroGel at no charge to qualifying patients who lack adequate insurance. Income eligibility thresholds are updated annually. In 2025, the household income limit was set at 400% of the federal poverty level for most products, though AndroGel's specific threshold may differ. Patients simultaneously enrolled in Medicaid are generally not eligible for manufacturer PAPs because the Medicaid rebate system prohibits manufacturers from providing direct benefits that overlap with Medicaid coverage.

Generic Substitution: The Single Fastest Cost Reduction

Switching from brand AndroGel to a generic testosterone gel 1% can reduce cash-pay cost from $400 to $600 per month to $30 to $80 per month at major pharmacy chains. GoodRx, NeedyMeds, and similar platforms aggregate pharmacy-specific coupons that may reduce generic testosterone gel cost to under $20 at certain pharmacies. These coupons cannot be combined with Medicaid but are useful during coverage gaps.

Testosterone Cypionate Injection as a Lower-Cost Alternative

Testosterone cypionate 200 mg/mL injection (generic) costs approximately $25 to $45 for a 10 mL vial, which provides roughly 20 injections at a standard 100 mg weekly dose. That translates to a per-dose cost below $3. A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism found no statistically significant difference in serum testosterone levels achieved between injectable and transdermal formulations when dosed appropriately, though patient preference and skin-transfer risk differ. See the 2018 Endocrine Society guideline on administration route selection.

Injections are not right for every patient. Those with needle phobia, bleeding disorders, or who cannot self-administer reliably may find topical gel more appropriate despite higher cost.

Telehealth and Compounding Pharmacies: What to Know

Several telehealth platforms prescribe compounded testosterone creams or gels through 503B outsourcing facilities. Compounded testosterone is not FDA-approved and is not covered by Medicaid. The FDA has stated that compounded drugs should be used only when an FDA-approved drug does not meet a patient's clinical need. FDA's compounding guidance is here. Patients considering compounded testosterone should discuss risks and regulatory status with their prescribing provider.

Can I Use HSA or FSA for AndroGel?

Yes. AndroGel is a prescription medication, and all IRS-qualifying Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) cover FDA-approved prescription drugs as qualified medical expenses under IRS Publication 502. This means you can use pre-tax HSA or FSA dollars to pay for AndroGel or its generics at any pharmacy that accepts your FSA/HSA debit card.

How HSA/FSA Savings Work in Practice

If you are in the 22% federal tax bracket and pay $60 per month for generic testosterone gel 1%, using HSA funds saves you approximately $13.20 per month in federal taxes ($158 per year) compared with paying out of pocket with after-tax income. The savings increase with higher tax brackets.

HSA accounts are only available to individuals enrolled in a High-Deductible Health Plan (HDHP). FSA accounts are employer-sponsored and do not require an HDHP. Neither HSA nor FSA funds can be used in combination with Medicaid-covered fills, because Medicaid pays for the prescription and there is no eligible out-of-pocket expense to reimburse.

Documentation Required for HSA/FSA Reimbursement

Keep your pharmacy receipt showing the prescription name, date, and amount paid. Most pharmacies that dispense AndroGel generate an itemized receipt automatically. If your FSA administrator requests documentation, a letter of medical necessity from your prescriber confirming hypogonadism diagnosis provides additional support, though it is rarely required for a straightforward prescription fill.

Clinical Efficacy Data That Supports Coverage Decisions

Understanding the clinical evidence behind AndroGel helps patients and providers make compelling arguments in PA letters and appeals.

Key Trial: T Trials (Testosterone Trials in Older Men)

The Testosterone Trials (T Trials) were a coordinated set of seven double-blind, placebo-controlled trials involving 790 men aged 65 years or older with serum testosterone below 275 ng/dL, published in the New England Journal of Medicine in 2016. Testosterone gel (1%) normalized serum testosterone in 87% of treated men at 12 months. The sexual function trial showed a statistically significant improvement in the Psychosexual Daily Questionnaire sexual desire score (mean difference 0.58; P<0.001). The vitality trial showed a statistically significant improvement in the PROMIS fatigue score. Full results are available at NEJM.

Skin-Transfer Risk: A Clinical Reason to Prefer 1.62% Gel

A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism found that AndroGel 1.62% delivers equivalent serum testosterone to AndroGel 1% at a lower application volume (40.5 mg vs. 100 mg per dose). Lower gel volume reduces the skin surface area exposed, which in turn reduces secondary exposure risk to partners and children. This pharmacokinetic difference can support a PA argument for brand 1.62% over generic 1% when household skin-transfer risk is documented. FDA label for AndroGel 1.62% is available here.

Cardiovascular Safety: What Prescribers Must Address in PA Letters

The FDA added a label warning in 2015 regarding a possible increased risk of cardiovascular events with testosterone products, based on reports from observational studies. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, subsequently showed that testosterone replacement in men with hypogonadism and high cardiovascular risk did not increase the rate of major adverse cardiovascular events (MACE) compared with placebo (hazard ratio 0.96; 95% CI 0.83 to 1.12; P<0.001 for non-inferiority). TRAVERSE results are here. PA letters submitted after mid-2023 can now cite TRAVERSE to address plan medical directors' cardiovascular concerns directly.

Working With Your HealthRX Provider to Secure Coverage

A HealthRX-affiliated provider who prescribes testosterone therapy can generate a PA request that includes all required elements from your state's form, both morning testosterone lab values, symptom documentation, and supporting literature citations. If your plan requires step therapy with generic testosterone gel first, your provider can order that formulation initially, monitor you for 30 to 60 days, and then document the outcome. That documentation becomes the step-therapy evidence needed for brand coverage if the generic is inadequate.

Providers on the HealthRX platform are licensed in all 50 states and are familiar with Medicaid-specific documentation requirements. Once your PA is approved, most state Medicaid plans authorize testosterone therapy for 12 months before requiring renewal, and many states allow auto-renewal if labs confirm continued therapeutic need.

For patients who remain uninsured or whose PA is denied after two appeal levels, the HealthRX team can assist with enrollment in myAbbVie Assist or identify the lowest-cost generic testosterone option available at pharmacies in your ZIP code. The TRAVERSE trial's non-inferiority finding for cardiovascular outcomes at 96% relative hazard means that clinical concern about cardiovascular risk is no longer a valid basis for blanket denial of testosterone therapy in appropriately diagnosed men, and a copy of the 2023 NEJM publication makes an effective exhibit in any Medicaid fair hearing.